Biologics have reshaped modern medicine, offering targeted and highly effective therapies for diseases once considered intractable. Among them, monoclonal antibodies
Biosimilars: Science, Need, and the Role of Governments in Shaping Access Over the last two decades, biologic medicines have
The Adalimumab Era, Reimagined: Interchangeability, Real-World Outcomes, and Access in the Biosimilar Age Adalimumab, a fully human monoclonal antibody targeting
The Future of Biopharma in the GCC: Investment Pathways and Strategic Gaps The Gulf Cooperation Council (GCC) is entering
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the landscape of cancer treatment, particularly in hematological malignancies like leukemia and
Biosimilars in Healthcare Economics: Enhancing Global Access to Medicine Date: July 2025 Healthcare systems globally are facing unprecedented economic
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
